Affimed (AFMD) Reports Q4 Loss of EUR0.16/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Affimed (AFMD) Reports Q4 Loss of EUR0.16/Share

Affimed Reports Financial Results for Fourth Quarter and Year End 2016

March 30, 2017 7:30 AM EDT

Heidelberg, Germany, March 30, 2017 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today reported financial results for the quarter and year ended December 31, 2016.

"Throughout 2016, we expanded our leadership position in NK-cell engagement and made considerable progress both with our clinical and preclinical programs," said Dr. Adi Hoess, CEO of Affimed. "We have successfully executed on our strategy to broaden our efforts in combination therapies, advancing our clinical trial for AFM13 with Merck's Keytruda as well... More